FDA granted approval to vemurafenib for Erdheim-Chester Disease. FDA granted regular approval to vemurafenib (ZELBORAF, Hoffmann-La Roche Inc.) for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation. More Information. November 6, 2017 Source 6d.